Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

NQO1 (NAD(P)H:quinone oxidoreduetase-1) is a cytosolic flavoprotein that catalyses the two-electron reduction of endogenous and environmental quinones. NQO1 plays a prominent role in protecting cells from the toxic effects of quinones, oxidative stress and more recently, the stabilisation of p53. Paradoxically, NQO1 is a target for anticancer drug development as reduction of certain quinones can generate cytotoxic species. Polymorphic variants of NQO1 have been characterised, two of which are known to cause a significant reduction in NQO1 protein (609C>T and 465C>T termed NQO1*2 and NQO1* 3,respectively). The incidence of the NQO1*2 allele is high in certain ethnic groups and the loss of NQO1 activity has potential implications for both the cancer susceptibility and the efficacy of quinone based anticancer drugs. Toxicity following exposure to benzene increases with lowered NQO1 activity and epidemiological evidence suggests that NQO1*2 is associated with an increased risk of developing certain types of cancer. Mitomycin C (MMC) is the major quinone based compound in routine clinical use and initial reports of reduced MMC efficacy in patients with the NQO1*2 allele are emerging. However, the role of NQO1 in metabolising MMC is complex and the relationship between NQO1 activity and response is controversial. It therefore remains to be determined whether NQO1 genotyping will significantly influence clinical decision making with respect to MMC therapy. Genotyping for NQO1 polymorphisms is however likely to play a significant role in the development and evaluation of other quinone based bioreductive drugs where NQO1 plays a more prominent role in drug activation.

Original languageEnglish
Pages (from-to)75-82
Number of pages8
JournalCurrent Pharmacogenomics
Volume2
Issue number1
DOIs
Publication statusPublished - 1 Mar 2004
Externally publishedYes

Fingerprint

Mitomycin
NAD
Quinones
Oxidoreductases
Alleles
Pharmaceutical Preparations
Flavoproteins
Poisons
Benzene
Ethnic Groups
Neoplasms
Oxidative Stress
Electrons
benzoquinone
Incidence
Proteins
Therapeutics

Cite this

@article{6552a3e94a484185a223307c0bf59772,
title = "Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)",
abstract = "NQO1 (NAD(P)H:quinone oxidoreduetase-1) is a cytosolic flavoprotein that catalyses the two-electron reduction of endogenous and environmental quinones. NQO1 plays a prominent role in protecting cells from the toxic effects of quinones, oxidative stress and more recently, the stabilisation of p53. Paradoxically, NQO1 is a target for anticancer drug development as reduction of certain quinones can generate cytotoxic species. Polymorphic variants of NQO1 have been characterised, two of which are known to cause a significant reduction in NQO1 protein (609C>T and 465C>T termed NQO1*2 and NQO1* 3,respectively). The incidence of the NQO1*2 allele is high in certain ethnic groups and the loss of NQO1 activity has potential implications for both the cancer susceptibility and the efficacy of quinone based anticancer drugs. Toxicity following exposure to benzene increases with lowered NQO1 activity and epidemiological evidence suggests that NQO1*2 is associated with an increased risk of developing certain types of cancer. Mitomycin C (MMC) is the major quinone based compound in routine clinical use and initial reports of reduced MMC efficacy in patients with the NQO1*2 allele are emerging. However, the role of NQO1 in metabolising MMC is complex and the relationship between NQO1 activity and response is controversial. It therefore remains to be determined whether NQO1 genotyping will significantly influence clinical decision making with respect to MMC therapy. Genotyping for NQO1 polymorphisms is however likely to play a significant role in the development and evaluation of other quinone based bioreductive drugs where NQO1 plays a more prominent role in drug activation.",
keywords = "cytosolic flavoprotein, Genotyping, cytotoxic, benzene",
author = "Phillips, {R. M.} and S. Basu",
year = "2004",
month = "3",
day = "1",
doi = "10.2174/1570160043476079",
language = "English",
volume = "2",
pages = "75--82",
journal = "Current Pharmacogenomics",
issn = "1570-1603",
number = "1",

}

Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1). / Phillips, R. M.; Basu, S.

In: Current Pharmacogenomics, Vol. 2, No. 1, 01.03.2004, p. 75-82.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1)

AU - Phillips, R. M.

AU - Basu, S.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - NQO1 (NAD(P)H:quinone oxidoreduetase-1) is a cytosolic flavoprotein that catalyses the two-electron reduction of endogenous and environmental quinones. NQO1 plays a prominent role in protecting cells from the toxic effects of quinones, oxidative stress and more recently, the stabilisation of p53. Paradoxically, NQO1 is a target for anticancer drug development as reduction of certain quinones can generate cytotoxic species. Polymorphic variants of NQO1 have been characterised, two of which are known to cause a significant reduction in NQO1 protein (609C>T and 465C>T termed NQO1*2 and NQO1* 3,respectively). The incidence of the NQO1*2 allele is high in certain ethnic groups and the loss of NQO1 activity has potential implications for both the cancer susceptibility and the efficacy of quinone based anticancer drugs. Toxicity following exposure to benzene increases with lowered NQO1 activity and epidemiological evidence suggests that NQO1*2 is associated with an increased risk of developing certain types of cancer. Mitomycin C (MMC) is the major quinone based compound in routine clinical use and initial reports of reduced MMC efficacy in patients with the NQO1*2 allele are emerging. However, the role of NQO1 in metabolising MMC is complex and the relationship between NQO1 activity and response is controversial. It therefore remains to be determined whether NQO1 genotyping will significantly influence clinical decision making with respect to MMC therapy. Genotyping for NQO1 polymorphisms is however likely to play a significant role in the development and evaluation of other quinone based bioreductive drugs where NQO1 plays a more prominent role in drug activation.

AB - NQO1 (NAD(P)H:quinone oxidoreduetase-1) is a cytosolic flavoprotein that catalyses the two-electron reduction of endogenous and environmental quinones. NQO1 plays a prominent role in protecting cells from the toxic effects of quinones, oxidative stress and more recently, the stabilisation of p53. Paradoxically, NQO1 is a target for anticancer drug development as reduction of certain quinones can generate cytotoxic species. Polymorphic variants of NQO1 have been characterised, two of which are known to cause a significant reduction in NQO1 protein (609C>T and 465C>T termed NQO1*2 and NQO1* 3,respectively). The incidence of the NQO1*2 allele is high in certain ethnic groups and the loss of NQO1 activity has potential implications for both the cancer susceptibility and the efficacy of quinone based anticancer drugs. Toxicity following exposure to benzene increases with lowered NQO1 activity and epidemiological evidence suggests that NQO1*2 is associated with an increased risk of developing certain types of cancer. Mitomycin C (MMC) is the major quinone based compound in routine clinical use and initial reports of reduced MMC efficacy in patients with the NQO1*2 allele are emerging. However, the role of NQO1 in metabolising MMC is complex and the relationship between NQO1 activity and response is controversial. It therefore remains to be determined whether NQO1 genotyping will significantly influence clinical decision making with respect to MMC therapy. Genotyping for NQO1 polymorphisms is however likely to play a significant role in the development and evaluation of other quinone based bioreductive drugs where NQO1 plays a more prominent role in drug activation.

KW - cytosolic flavoprotein

KW - Genotyping

KW - cytotoxic

KW - benzene

UR - http://www.scopus.com/inward/record.url?scp=3042806548&partnerID=8YFLogxK

U2 - 10.2174/1570160043476079

DO - 10.2174/1570160043476079

M3 - Review article

AN - SCOPUS:3042806548

VL - 2

SP - 75

EP - 82

JO - Current Pharmacogenomics

JF - Current Pharmacogenomics

SN - 1570-1603

IS - 1

ER -